Increasing health insurance coverage and access to usual source of care necessary to meet targets.
The term "personalized medicine" remains an overused promise to apply specific treatment plans.
Researchers find a 23% increased risk of death among patients who received a transfusion during surgery or post-operative hospitalization.
Increased perinephric fat is associated with increased blood loss and operative time, study shows.
The estimated recurrence rate at 10 years was 88.3%, data show.
Seventeen percent of Americans think that there is nothing people can do to change their risk.
Benefits in cancer-linked symptoms mediated by lower Impact of Event Scale one month after intervention.
Diabetes also found to increase cancer-specific mortality in patients with clear cell renal cell carcinoma.
ACE inhibitors and angiotensin receptor blockers were shown to prolong median overall survival by nine months.
Death from PCa is down 45% from peak rates, but more than 29,000 men are projected to die from PCa in 2014.
The five-year cancer-specific and overall survival rates were 100% and 97.8%, respectively.
Renal tissue could one day be created that would be functional as well as completely immunocompatible.
Active smoking shortens progression-free and overall survival, study finds.
Patients with blood group O have a lower risk of lymph node metastases but a higher risk of bilateral disease.
Innovative approaches offer the potential for effective treatments to limited target areas with improved side effect profiles.
Patients aged 75-79 who had localized tumors had worse cancer-specific survival with nonsurgical management than surgery.
Patients with this malignancy had a 73% prevalence of simple renal cysts.
Only 9.5% of the study participants were told about the possibilities of overdiagnosis and overtreatment by their physicians.
Most want to be told of screening harms, but only 9.5 percent informed about overdiagnosis, overtx.
Recurrence that occurs more than 48 months after surgery is no longer significantly associated with reduced survival from renal cell carcinoma.
A phase 3 trial has found pazopanib (Votrient) and sunitinib (Sutent) are both equally effective for treating metastatic kidney cancer.
Researchers observe a high rate of local disease control with increased progression-free survival.
It improves predictions of perioperative complication risks, according to researchers.
In a head-to-head trial, patients had similar progression-free survival with pazopanib and sunitinib, but experienced fewer adverse effects.
Renal cancers were found in 5% of patients with autosomal dominant polycystic kidney disease.
The beneficial impact of this approach on renal function does not improve survival, however.
Recent studies provide persuasive evidence that the majority of small renal masses will grow slowly over time.
Dr. Crispen highlights the advantages and challenges of active surveillance for small renal masses.
Highest intake found to increase the risk of renal pelvis and ureter cancers 11-fold.
Robotic-assisted kidney cancer surgery appears to be associated with more "excessive" hospital charges.